Separation of terbium as a first step towards high purity terbium-161 for medical applications-Reference-Cited by-同舟云学术

Separation of terbium as a first step towards high purity terbium-161 for medical applications

Published:2024 Issue:28 Volume:14 Page:19926-19934
ISSN:2046-2069
Container-title:RSC Advances
language:en
Short-container-title:RSC Adv.

Author:

Arman Meryem Özge¹²^ORCID,Mullaliu Angelo¹,Geboes Bart²^ORCID,Van Hecke Karen²^ORCID,Das Ganghadar³^ORCID,Aquilanti Giuliana³^ORCID,Binnemans Koen¹^ORCID,Cardinaels Thomas¹²^ORCID

Affiliation:

1. KU Leuven, Department of Chemistry, Celestijnenlaan 200F, P.O. 2404, B-3001 Leuven, Belgium

2. Belgian Nuclear Research Centre SCK CEN, Institute for Nuclear Energy Technology, Boeretang 200, Mol, B-2400, Belgium

3. Elettra Sincrotrone Trieste, 34149 Basovizza, Trieste, Italy

Abstract

An electrochemical and chromatographic approach to purification of the medical radiolanthanide terbium-161.

Funder

Fonds Wetenschappelijk Onderzoek

Publisher

Royal Society of Chemistry (RSC)

Link

http://pubs.rsc.org/en/content/articlepdf/2024/RA/D4RA02694B

Reference53 articles.

1. CERN Courier, Terbium: a new ‘Swiss army knife’ for nuclear medicine, https://cerncourier.com/a/terbium-a-new-swiss-army-knife-for-nuclear-medicine/ , accessed 16 March 2020

2. A Unique Matched Quadruplet of Terbium Radioisotopes for PET and SPECT and for α- and β−-Radionuclide Therapy: An In Vivo Proof-of-Concept Study with a New Receptor-Targeted Folate Derivative

3. The low-energy β− and electron emitter 161Tb as an alternative to 177Lu for targeted radionuclide therapy

4. 161Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer

5. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model